Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
about
Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinomamTOR inhibitors in cancer therapyThe ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker.Down-regulation of C12orf59 is associated with a poor prognosis and VHL mutations in renal cell carcinoma.Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disordersIdentification of DEP domain-containing proteins by a machine learning method and experimental analysis of their expression in human HCC tissues.Discovering potential driver genes through an integrated model of somatic mutation profiles and gene functional information.Targeting Signaling Transduction Pathways in Bladder Cancer.Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma.Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.Recent advances in targeting mTOR signaling pathway using small molecule inhibitors.mTORC1 senses stresses: Coupling stress to proteostasis.Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth.Genetics of renal cancer: focus on MTOR.Hypoxia tolerance, longevity and cancer-resistance in the mole rat Spalax - a liver transcriptomics approach.mTOR Pathways in Cancer and Autophagy.Mechanistic Insights into the Differential Catalysis by RheB and Its Mutants: Y35A and Y35A-D65A.Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update
P2860
Q26766240-4E18A52C-B475-4AB2-9B34-3B0BBA37E7BAQ28079129-F0054058-05F5-4655-8A51-A4BBAB3D6E39Q36729436-EBE0DA8D-CC81-4062-8C53-9B184B46162BQ36916355-316861DB-84F0-44FB-ABD2-944DB24FAB67Q37217474-24FBA2E1-AEDA-47B5-AE84-9B527E4B4007Q37437248-3B1648EA-C70E-488B-AD5A-2F78016218E4Q37522321-AB781116-BE1E-412A-AB21-44BE51769794Q38429590-4C38C91C-F660-4A06-8D9B-8EAAD3BB5FADQ38608540-FFA6D4F4-344C-482F-A78F-A1A2572CF2ABQ38832513-767B0347-D305-4E89-8CD1-DD6179D9056FQ38914374-E6328F89-B45B-417C-A612-40AE743FDA3EQ38955246-D5BD2349-081F-46EE-9F32-17BC12B88E45Q39179555-ED01CEE4-5E46-4D7D-99A4-1B404349E57CQ42809090-E1B867C5-A80F-46FB-978C-BAE8981801AAQ42878855-C2FD0BCA-C091-407C-BC48-DC2E3C4541CEQ43462854-368CF9EC-6565-4C4A-8AD2-8B5339279950Q49259139-B8928BD4-E444-4348-86E4-935A5DC95596Q55253300-C43EAE1D-9213-4DD2-BC0F-75CC13BFFD2CQ56378380-247E39B8-B809-40CD-B68F-2F1F16F039B0
P2860
Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
@en
type
label
Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
@en
prefLabel
Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
@en
P2093
P2860
P50
P356
P1433
P1476
Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
@en
P2093
Arindam P Ghosh
Mary E Ballestas
Mary-Ann Bjornsti
Richard Kirkman
Sunil Sudarshan
Tatjana Coric
P2860
P304
17895-17910
P356
10.18632/ONCOTARGET.4963
P407
P577
2015-07-01T00:00:00Z